Very recently, Basilion and coauthors constructed a targeted nanocomposite, Au-Gd3+-prostate-specific membrane antigen (PSMA) NPs for MRI-guided radiotherapy of prostate cancer by immobilization of the Gd3+-complex and prostate-specific membrane antigen (PSMA) targeting ligands on the monodispersing Au NPs (as shown in Figure 4a) [50]. Here, FOLH1 is linked to prostate carcinoma.